Findings from the NELSON study demonstrate that the use of computed tomography screening among asymptomatic men at high risk for lung cancer led to a 26 percent (9-41%, 95% CI) reduction in lung cancer deaths at 10 years of study follow-up (at 86% compliance).
Imfinzi (durvalumab) reduced the risk of death by nearly one-third compared to placebo in the phase III PACIFIC trial.
Genentech announced positive results from the phase III IMpower133 study of Tecentriq (atezolizumab) plus carboplatin and etoposide for the initial treatment of people with previously-untreated extensive-stage small cell lung cancer.
Findings from a recent study demonstrate that the use of atezolizumab, a PD-L1 inhibitor, in combination with carboplatin plus pemetrexed as first-line therapy and pemetrexed as maintenance therapy improves progression free survival in patients with stage IV non-squamous non-small cell lung cancer.
Myriad Genetics announced that results from a landmark study of variant classifications following hereditary cancer genetic testing were published in the Journal of the American Medical Association.
Takeda Pharmaceutical Co. Ltd. announced results from the phase III ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line) trial, demonstrating that Alunbrig reduced the risk of disease progression or death, known as progression-free survival, as assessed by a blinded independent review committee, by more than 50 percent compared to crizotinib in adults with anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer who had not received a prior ALK inhibitor.
Opioid use among cancer patients does not appear to be leading to the steep increase of overdoses seen in the general public, according to a study by Duke Cancer Institute researchers.
Even when they had good health insurance coverage, women with breast cancer reported having financial worries related to their care, and the vast majority said they preferred to know about treatment costs at the time of diagnosis.
Initial results from the first North American clinical study of CIMAvax-EGF show that this Cuban-developed immunotherapy is safe, well tolerated and worthy of further study. Principal Investigator Grace Dy, of Roswell Park Comprehensive Cancer Center, presented the findings at the International Association for the Study of Lung Cancer's 19th World Conference on Lung Cancer in Toronto, Canada.
Anne-Marie Langevin, of the South Texas Pediatric Minority/Underserved NCI Community Oncology Research Program site in San Antonio, won the 2018 Harry Hynes Award, which is given annually to the PI who reflects the outstanding contribution to clinical trials and community research.
